Proprietary probiotic strain supports weight management in recent study

Previous animal research found that the probiotic strain produces the appetite-suppressing peptide ClpB, reducing weight gain and adiposity in rodent models of obesity.

A recent study1 published in Nutrients found that Hafnia alvei HA4597 (HA), a probiotic strain from French biotech company TargEDys, helped subjects lose weight. Previous animal research found that the probiotic strain produces the appetite-suppressing peptide ClpB, reducing weight gain and adiposity in rodent models of obesity.

In the prospective, double-blind, randomized study, 236 overweight adults who were randomized to receive either placebo or two capsules per day of Hafnia alvei HA4597 for 12 weeks. The primary endpoint was the percentage of subjects achieving a weight loss of at least 3% after 12 weeks. In the HA group, significantly more subjects (+33%) met the primary endpoint than in the placebo group (54.9 vs. 41.4%). In the HA group, an increased feeling of fullness and a greater loss of hip circumference at 12 weeks were also observed. Fasting glycemia at 12 weeks was significantly lower in the HA compared to the placebo group. 

"This will be a game-changer in the sector of weight management, with finally a solution that meets consumers expectations in terms of safety and naturality, while also bringing a real, demonstrated efficacy based on molecular mimicry and the biochemical regulation of appetite,"says Grégory Lambert, CEO of TargEDys.

Reference

  1. Déchelotte P et al. "The probiotic strain H. alvei HA4597 improves weight loss in overweight subjects under moderate hypocaloric diet: a proof-of-concept, multicenter randomized, double-blind placebo-controlled study." Nutrients, vol. 13 (2021):1902